Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate

Mucin glycoprotein 1 (MUC1) is a glycosylated transmembrane protein on epithelial cells. We investigate MUC1 as a therapeutic target in Barrett's epithelium (BE) and esophageal adenocarcinoma (EA) and provide proof of concept for a light based therapy targeting MUC1. MUC1 was present in 21% and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2017-04, Vol.8 (15), p.25080-25096
Hauptverfasser: Adil Butt, Mohammed, Pye, Hayley, Haidry, Rehan J, Oukrif, Dahmane, Khan, Saif-U-Rehman, Puccio, Ignazio, Gandy, Michael, Reinert, Halla W, Bloom, Ellie, Rashid, Mohammed, Yahioglu, Gokhan, Deonarain, Mahendra P, Hamoudi, Rifat, Rodriguez-Justo, Manuel, Novelli, Marco R, Lovat, Laurence B
Format: Artikel
Sprache:eng
Schlagworte:
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Antineoplastic Agents, Immunological - pharmacology
Biomarkers
Cell Line, Tumor
Cell Survival - drug effects
Computational Biology
Disease Progression
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - genetics
Esophageal Neoplasms - metabolism
Esophageal Neoplasms - pathology
Gene Expression Profiling
Gene Expression Regulation, Neoplastic - drug effects
Glycoproteins - genetics
Glycoproteins - metabolism
Humans
Immunoconjugates - pharmacology
Immunohistochemistry
Light
Mucin-1 - genetics
Mucin-1 - metabolism
Neoplasm Grading
Neoplasm Metastasis
Research Paper
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mucin glycoprotein 1 (MUC1) is a glycosylated transmembrane protein on epithelial cells. We investigate MUC1 as a therapeutic target in Barrett's epithelium (BE) and esophageal adenocarcinoma (EA) and provide proof of concept for a light based therapy targeting MUC1. MUC1 was present in 21% and 30% of significantly enriched pathways comparing BE and EA to squamous epithelium respectively. MUC1 gene expression was x2.3 and x2.2 higher in BE (p=
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.15340